Navigation Links
JCI early table of contents for April 15, 2013
Date:4/15/2013

Researchers untangle molecular pathology of giant axonal neuropathy

Giant axonal neuropathy (GAN) is a rare genetic disorder that causes central and peripheral nervous system dysfunction. GAN is known to be caused by mutations in the gigaxonin gene and is characterized by tangling and aggregation of neural projections, but the mechanistic link between the genetic mutation and the effects on neurons is unclear. In this issue of the Journal of Clinical Investigation, Robert Goldman and colleagues at Northwestern University uncover how mutations in gigaxonin contribute to neural aggregation.They demonstrated that gigaxonin regulates the degradation of neurofilament proteins, which help to guide outgrowth and morphology of neural projections. Loss of gigaxonin in either GAN patient cells or transgenic mice increased levels of neurofilament proteins, causing tangling and aggregation of neural projections. Importantly, expression of gigaxonin allowed for clearance of neurofilament proteins in neurons. These findings demonstrate that mutations in gigaxonin cause accumulation of neurofilament proteins and shed light on the molecular pathology of GAN.

TITLE: Giant axonal neuropathy-assoicated gigaxonin mutations impair intermediate filament protein degradation

AUTHOR CONTACT:
Robert Goldman
Northwestern University Medical School, Chicago, IL, USA
Phone: 312-503-4215; E-mail: r-goldman@northwestern.edu

View this article at: http://www.jci.org/articles/view/66387?key=fbb27aa987681b6b9d6a


Resistance is futile: researchers identify gene that mediates cisplatin resistance in ovarian cancer

Platinum compounds, such as cisplatin and carboplatin, induce DNA cross-linking, prohibiting DNA synthesis and repair in rapidly dividing cells. They are first line therapeutics in the treatment of many solid tumors, but cancer cells frequently develop resistance to these drugs. Mechanisms of resistance typically include reduced platinum uptake and increased platinum export. In this issue of the Journal of Clinical Investigation, Anil Sood and colleagues at M.D. Anderson Cancer Center identified a cellular membrane protein, ATP11B, that mediates cisplatin resistance in ovarian cancer cells. They found that ATP11B expression was correlated with higher tumor grade in human ovarian cancer samples and with cisplatin-resistance in human ovarian cancer cell lines. Further, loss of ATP11B restored the sensitivity of ovarian cancer cell lines to cisplatin and reduced ovarian tumor growth in mice. These findings suggest that ATP11B could serve as a therapeutic target to overcome cisplatin resistance.

TITLE: ATP11B mediates platinum resistance in ovarian cancer

AUTHOR CONTACT:
Anil Sood
M. D. Anderson Cancer Center, Houston, TX, USA
Phone: 713-745-5266; Fax: 713-792-7586; E-mail: asood@mdanderson.org

View this article at: http://www.jci.org/articles/view/65425?key=1b568a84b2ed6f3104ee


ALSO IN THIS ISSUE

TITLE: RNA binding protein PCBP2 modulates glioma growth by regulating FHL3

AUTHOR CONTACT:
Xiaozhong Peng
Institute of Basic Medical Sciences & School of Basic Medicine,Chinese Acad, Beijing, CHN
Phone: 0086-010-65296434; E-mail: peng_xiaozhong@163.com

View this article at: http://www.jci.org/articles/view/61820?key=1198455a7ca0e03c53ba

TITLE: IL-33 dependent induction of allergic lung inflammation by FcγRIII signaling

AUTHOR CONTACT:
Anne Sperling
University of Chicago, Chicago, IL, USA
Phone: 773-834-1211; Fax: 773-702-4736; E-mail: asperlin@uchicago.edu

View this article at: http://www.jci.org/articles/view/63802?key=032761d160603a5e9093

TITLE: WNT signaling underlies the pathogenesis of neuropathic pain in rats

AUTHOR CONTACT:
Xue-Jun Song
Parker University Research Institue, Dallas, , USA
Phone: 9734386932 EXT 7144

View this article at: http://www.jci.org/articles/view/65364?key=b983094cb01c7ee80e34

TITLE: Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs

AUTHOR CONTACT:
Cynthia E. Dunbar
NIH, National Heart, Lung and Blood Institute, Bethesda, MD, USA
Phone: 301 496 1434; Fax: 301-496-8396

View this article at: http://www.jci.org/articles/view/67146?key=2d1d1346d4a5bb96bb80

TITLE: Opposing chemokine gradients control human thymocyte migration in situ

AUTHOR CONTACT:
Ellen Robey
University of California, Berkeley, Berkeley, CA, USA
Phone: 510-642-8669

View this article at: http://www.jci.org/articles/view/67175?key=ea0f0474c71bcec79110

TITLE: GM-CSF contributes to aortic aneurysms resulting from SMAD3 deficiency

AUTHOR CONTACT:
Jiahong Xia
Union Hospital, Tongji Medical College, Huazhong University of Science and, Wuhan, CHN
Phone: 0086-13971038472; Fax: 0086-27- 85726337; E-mail: jiahong.xia@mail.hust.edu.cn

View this article at: http://www.jci.org/articles/view/67356?key=481605675f72b402a894

TITLE: Mer receptor tyrosine kinase is a novel therapeutic target in melanoma

AUTHOR CONTACT:
Douglas Graham
Univ of Colorado Anschutz Medical Campus, Aurora, CO, USA
Phone: 303-724-4006; Fax: 303-724-4015; E-mail: doug.graham@ucdenver.edu

View this article at: http://www.jci.org/articles/view/67816?key=c3beb1f407a41392c648


'/>"/>

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. Fosamax Lawsuit Update: Bernstein Liebhard LLP Notes Nearly 2,600 Claims Alleging Fosamax Femur Fractures, Other Side Effects, Pending in New Jersey State Litigation
2. Living Well Assisted Living at Home Hosts Ongoing Support Group for Patients with Early Onset Alzheimer’s
3. Hospitals Work to Reduce Unnecessary Early Births
4. JCI early table of contents for April 8, 2013
5. Causes of migraines nearly impossible to determine
6. Nearly 30 Percent of Americans Have High Blood Pressure: CDC
7. Cartilage Gives Early Warning of Arthritis, Study Finds
8. JCI early table of contents for April 1, 2013
9. Early COPD diagnosis possible with nuclear medicine
10. Blood Test Might Spot Pancreatic Cancer Early, Study Finds
11. New metabolite-based diagnostic test could help detect pancreatic cancer early
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... Illustrate, Maintain® methodology and industry-leading compliance software, The Guard®, has helped another long-time ... Rights (OCR) HIPAA audit and properly satisfy the law. , Thanks to the ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... and social campaign, “Humans With Vaginas.” The goal is to ignite conversation via ... non-toxic personal care products. The brand has declared September “Humans with Vaginas” month, ...
(Date:9/20/2017)... ... 20, 2017 , ... Medicare doesn’t have the authority to ... for their prescription drugs, according to a new comparison of drug plans by ... behalf, there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Trials I Face to Receive ... he emotionally pens his aspirations and goals to better one’s life through God. “The ... Green, while searching in all the wrong places, found a love for writing. Green ...
(Date:9/20/2017)... ... September 20, 2017 , ... Houston, Texas, investment firm CORDA Investment ... 8, and Monday, September 11, off work and rolled up their sleeves to help ... to local homes to start the process of rebuilding. , CORDA founder Bonner C. ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/7/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), ... cell and tissue hypothermic storage and cryopreservation ... President and CEO, will be presenting at two investment conferences ... 19 th Annual Global Investment Conference on Tuesday, September ... The conference is being held at the New York Palace ...
Breaking Medicine Technology: